Multiple small molecule leads for an undisclosed target nominated by Almirall were the subject of this achievement. HitGen will grant exclusive rights to Almirall for further development and commercialization, and be eligible for preclinical and clinical milestone payments.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 26, 2020